- AI-screener
- Securities US
- Novo Nordisk A/S
Novo Nordisk A/S
$70.73
$1.01
1.45%
24 Jun 20:00
$57.00
$145.99
52 weeks low/high
Technical analysis
- Trend ClassDown and flat
- Trend PowerStrong trend
- PatternDivergence Channel
- EMA-20Bearish reversal2025-06-20 the price crossed down the moving average line and formed a short-term downside trend.
- EMA-50Bearish reversalThe price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.
- EMA-100Bearish reversal2025-06-17 the price crossed down the moving average line and formed a short-term downside trend.
- StochasticBearish WeakeningThe stochastic indicator is in the oversold territory and it grows. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.
- RSIBearishRSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.
- MACDBearish reversalOscillator MACD is in the positive territory it's lower than the signal line and falls. These factors mean that the growing period is over. Last signal: main and signal line crossing.
- Candle pattern typeDeliberation Block FormationConsists of three black bodies with consecutively lower closes in a downtrend. The final day is a short black candlestick, a spinning top or a doji. Considered to be a bullish reversal pattern.Date of signal:
Prices and risks
Price
| Change | Change by industry | Min. | Max. | Volume | |
|---|---|---|---|---|---|
| Yesterday | -0.79% | 1.53% | $69.86 | $71.04 | 393.57M |
| Week | -6.53% | 2.79% | $68.54 | $74.82 | 1.85B |
| Month | 3.61% | 3.26% | $66.60 | $81.44 | 10.06B |
| 3 Months | -8.16% | 2.67% | $57.00 | $81.44 | 29.88B |
| 6 Months | -21.61% | 20.72% | $57.00 | $93.80 | 58.28B |
| Year | -52.11% | 17.17% | $57.00 | $148.15 | 106.27B |
| 3 years | 24.66% | 75.17% | $47.51 | $148.15 | 212.38B |
| 5 years | 110.67% | 99.48% | $31.61 | $148.15 | 245.39B |
| All time | 7,729.63% | 61.81% | $0.95 | $148.15 | 178.49B |
Volatility
| NVO | By industry | |
|---|---|---|
| Yesterday | 9.63% | 1.05% |
| Week | 4.71% | 1.90% |
| Month | 9.25% | 11.45% |
| 3 Months | 19.94% | 21.81% |
| 6 Months | 29.37% | 29.80% |
| Year | 43.96% | 38.55% |
| 3 years | 62.15% | 81.88% |
| 5 years | 73.06% | 114.89% |
| All time | — | — |
Risk ratios
- Sortino
- -0.89
- Sharpe
- -1.16
- Sterling
- -0.84
- Liquidity index
- 6.68
- Alpha
- 0.00148
- Beta
- 0.39
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$236.36B
Capitalization
3.39B
Shares outstanding
Health Care
Sector
Pharmaceuticals
Industry
Mr. Lars Fruergaard Jorgensen
CEO
Website
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.